Sign up to receive the latest HAMODIA emails
Oxford University announced Saturday that it will resume a trial for a coronavirus vaccine along with pharmaceutical company AstraZeneca, a resolution that occurs days after the test was discontinued due to an informed side effect on a British patient.
In a statement, the university showed a reboot at all of its test sites in the UK after regulators gave go-ahead after Sunday’s break.
“The indefinite review procedure has come to an end and following the recommendations of the indefinite protection review committee and uk regulator MHRA will resume trials in the UK,” he said.
The vaccine being developed through Oxford and AstraZeneca is widely recognized as one of the leading applicants among dozens of test-stage coronavirus vaccines worldwide.
UK Health Secretary Matt Hancock welcomed the reboot and said it’s “good news for everyone” that control “works again. “
The university said that in giant trials like this, “some participants are expected to become ill and that each case will have to be thoroughly evaluated to ensure a full protection assessment.
He said around 18,000 international people have won their vaccine in Britain, Brazil and South Africa. Approximately 30,000 volunteers are being recruited in the United States.
Although Oxford reveals data on the patient’s illness due to the confidentiality of the participants, an AstraZeneca spokesperson said this week that a woman had developed severe neurological symptoms that caused the break. Specifically, the woman developed symptoms consistent with transverse myelitis, a rare disease. inflammation of the spinal cord.
The university presses that it is “committed to protecting our participants and the criteria for conduct in our studies and will continue to monitor protection closely. “
Disruptions in drug trials are and the suspension of transitoryness caused a sharp drop in the percentage value of AstraZeneca after Tuesday’s announcement.
The Oxford-AstraZeneca test was already suspended in July for several days after a player developed neurological symptoms that turned out to be an undiagnosed case of sclerosis that the researchers declared unrelated to the vaccine.
During the third and final level of testing, researchers look for any symptoms of imaginable side effects that may not have been found in previous research with patients. Due to their giant size, studies are considered the most important exploration phase for tripping. Trials also evaluate efficacy by monitoring who gets sick and who is not among patients receiving the vaccine and those receiving a dummy injection.
Dr. Charlotte Summers, senior professor of intensive care medicine at the University of Cambridge, said the breakup is a sign that the Oxford team prioritizes protection problems, but that it generates “a lot of unnecessary speculation. “
“To combat the global COVID-19 pandemic, we want to expand the vaccines and treatments that other people are comfortable using, so it is imperative to the public trust that we stick to the evidence and do not draw conclusions until the data is available. , “she said . .
Scientists and stakeholders around the world, as well as experts from the World Health Organization, have sought to involve expectations of imminent progress for coronavirus vaccines, noting that vaccine trials are rarely simple.
Italian Health Minister Roberto Speranza welcomed the resumption of the vaccine trial, but warned that caution is still needed.
“Science is in paints to give effective remedies and vaccines globally,” he said. “In the meantime, the key remains our behavior. “
Italy, which is point 0 of the epidemic in Europe, is one of the leading countries investing in the AstraZeneca vaccine.
Two vaccines are undergoing mass last-stage testing in the United States, one manufactured through Moderna Inc. Pfizer and the German company BioNTech.